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Abstract
Background: Recently, tumor initiating cells (TICs), which possess self-renewal and other stem cell properties, are
regarded as the cause of tumor initiation, recurrence and metastasis. The isolation and identification of TICs could
help to develop novel therapeutic strategies.
Methods: In this study, we isolated spheroid cells from human renal cell carcinoma (RCC) cell line SN12C in stem
cell-conditioned medium. The stemness characteristics of spheroid cells, including tumorigenicity, self-renewal,
proliferation and aldehyde dehydrogenase (ALDH) activity were evaluated; the expression levels of stemness genes
and related proteins were assessed. Furthermore, study examined the differentiation of TICs into endothelial cells
and the relationship between TICs and EMT.
Results: Our data demonstrated that spheroid cells cultured in defined serum-free medium possessed TIC properties,
such as high tumorigenic capacity, upregulation of TIC-related genes and proteins, persistent self-renewal and
extensive proliferation. Furthermore, spheroid cells were more aggressive in growth, invasion, scratch recovery,
clonogenic survival and high aldehyde dehydrogenase (ALDH) activity. Interestingly, a marked increase in tumor
vascularity compared to adherent tumors in vivo, and spheroid cells can differentiate into functional endothelial-like
cells in vitro suggesting a role of tumor initiating cells in tumor angiogenesis. The spheroid cells also demonstrated
down-regulated E-cadherin and up-regulated Vimentin expression, which is the typical phenotype of EMT.
Conclusions: These results suggest that spheroid cells with tumor initiating cells-like characteristics contributed to
tumor generation, progression, high tumorigenicity, pro-angiogenic capability and relationship with EMT. Further
experiments using more refined selection criteria such as a combination of two or multiple markers would be useful to
specifically identify and purify TICs.
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Background
Renal cell carcinoma (RCC) is one of the commonest
malignancies of the genitourinary tract accounting for
61,560 new cases and 38,270 deaths in the United States
per annum [1]. Patients with RCC still face a dismal
clinical outcome owing to high rate of metastasis both at
initial presentation and after radical nephrectomy
despite considerable improvements have been made in
diagnosis, surgical techniques and adjuvant therapies in
last decades [2]. Therefore, it is important to understand
the molecular mechanism involved in the essence and
origin of RCC. Identification of novel biomarkers associ-
ated with disease progression and metastasis of RCC
and combination of their application with traditional
diagnostic and prognostic parameters would contribute
to development of effective strategies for the prevention,
early diagnosis and treatment of RCC.
It has been assumed that tumor initiating cells (TICs)
constitute a reservoir of self-sustaining cells with ability
to self-renew and maintain the tumor [3–5]. A series of
studies indicate that TICs may be the origin of local
recurrence and distant metastases, if they were not
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completely eradicated by conventional treatments [6–11].
Evidence is accumulating that TICs have been isolated
from several types of human tumors, such as breast
cancer and brain tumors [6, 12]. However, the literature of
investigating stem cells of kidney cancers is limited and
lack of TIC-specific cell surface antigen markers. Cur-
rently, there are data to demonstrate that “sphere forming
cells” or “spheroids” are commonly found and are useful
to enrich the potential TIC subpopulations when the spe-
cific TIC makers have not been defined, as is the case for
most TICs [13, 14]. Therefore, in the present study, we
isolated spheroid cells from RCC cell line (SN12C) and
determined whether these cells acquired TICs characteris-




Human RCC cell line, SN12C was used for this study which
was obtained from the Type Culture Collection of Chinese
Academy of Sciences (Shanghai, China). SN12C were
cultured in DMEM (Gibco, California, USA) medium. Both
media contained 10 % fetal bovine serum (FBS, Gibco).
Spheroid cells were derived by placing in serum-free
medium (SFM) consisting of DMEM/F-12 medium with
20 ng/ml EGF (Invitrogen), 20 ng/ml bFGF (Invitrogen)
and B27 (Invitrogen) on poly (2-hydroxyethylmethacrylate)
(poly-HEMA; Sigma-Aldrich)-precoated plates. After pri-
mary spheroid body reached the size of approximately
100–200 cells per spheroid body, the spheroid bodies were
dissociated at the density of 1000 cells per milliliter and 100
single cell suspension (100 μl) was seeded in each well of a
96-well ultra-low attachment plate (Corning) in serum-free
medium described above. Two weeks later, wells were
analyzed for subspheroid body formation.
Evaluation of tumorigenicity and histologic staining
All animal studies adhered to protocols approved by the
local Institutional Animal Care and Use Committee. Five--
week-old female BALB/C nude mice were purchased from
the Animal Institute of Peking Union Medical College
(PUMC). To assess tumorigenicity of spheroid cells and
adherent cells, firstly, 104,105,106,107 cells of SN12C adher-
ent cells were injected respectively into the right armpit,
right inguen, left inguen and left armpit of the nude
mouse(n = 3); 103,104,105,106 cells of SN12C spheroid cells
were injected respectively into the right armpit, left armpit,
left inguen and right inguen of the nude mouse(n = 3);
secondly, 105 cells of spheroid cells and adherent cells were
injected s.c. respectively into the left and right inguen of the
same nude mouse (n = 3), to comparatively evaluate their
tumorigenic potential. Mice were sacrificed by cervical
dislocation at a tumor diameter of 1 cm or at 6 months
post-transplantation. H&E staining was done on 4 μm
paraffin-embedded sections following standard protocols.
Immunohistochemistry
Tumor specimens were fixed with buffered formalin and
embedded in paraffin. Sections (5 mm) were placed on
glass slides, heated at 60 °C for 20 min, and then
deparaffinized with xylene and ethanol. For antigen
retrieval, tumor specimens mounted on glass slides were
immersed in preheated antigen retrieval solution for
20 min and allowed to cool for 20 min at room
temperature. After the inactivation of endogenous
peroxidase, rat anti mouse (1:50 dilution) or mouse anti
human CD34 (1:200 dilution) (santa cruz) were then
added, and incubated overnight at 4 °C. The second anti-
body was detected with a biotinylated anti-rat or anti-
mouse IgG (DAKO). Diaminobenzidine tetrahydrochlo-
ride was then added for development for 10 min,
followed by counterstaining with hematoxylin solution.
CD34/PAS double-stained was used to validate vasculo-
genic mimicry (VM). It was identified by the detection
of PAS-positive loops surrounding with tumor cells (not
endothelial cells), with or without red blood cells in it.
Microvessel density (MVD) was determined by light
microscopy examination of CD34-stained sections at the
“hot spot”. The fields of greatest neovascularization were
identified by scanning tumor sections at low power
(×100). The average vessel count of three fields (×400)
was regarded as the MVD.
Immunofluorescence
The primary antibodies were CD133-PE (1:50, Miltenyi
Biotec), CD44 (1:400; Santa Cruz), CD105 (1:100; Santa
Cruz), Oct4 (1:100; Santa Cruz) and Nanog (1:200; Santa
Cruz). The second antibody was incubated with FITC-
labeled goat anti-mouse IgG (1:200; SantaCruz). All were
prepared according to the Manufacturer’s protocols. Cells
were fixed with 4 % of paraformaldehyde and when needed,
permeabilized with 0.05 % of Triton X-100 in PBS at room
temperature for 20 min. Samples were blocked with 1 % of
bovine serum albumin (Sigma) and incubated with
appropriate primary antibody at 37 °C for 1 h. After wash-
ing extensively, they were incubated with second antibody
at 37 °C for 1 h. After immunolabeling and washing
procedure, nuclei were then counterstained with 4′6-diami-
dino-2-phenylindole (DAPI; Sigma). Coverslips were viewed
under fluorescence microscopy (Olympus LX51, Tokyo,
Japan) and photos were taken using 100-fold magnification.
Flow cytometry
Monolayer cells were detached from culture plates with
0.25 % trypsin (Gibco), and spheroids were collected and
dissociated by 5–10 min digestion with trypsin. Viable
cell number was determined using Trypan blue staining
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(Invitrogen). Antibodies analyses were carried out as
previously described [15]. The following anti-human
monoclonal antibodies were used for flow cytometry:
CD133-PE, CD44, CD105, Nanog, Oct4 and FITC con-
jugated goat anti-mouse IgG. Appropriate isotype con-
trols were used for each antibody.
Reverse transcription polymerase chain reaction (RT-PCR)
We examined the expression of CD44, renal stem/progeni-
tor genes (CD133, CD105), and pluripotency gene (Oct4,
Nanog) by semiquantitative reverse transcription–polymer-
ase chain reactions (RT-PCR). The primers are provided in
Table 1. Total RNA was extracted from spheroid cells and
adherent cells following manufacturer’s instructions. RNA
was quantified by spectrophotometry at OD260. The target
cDNA was amplified using Platinum Taq DNA Polymerase
(Invitrogen) for 28–30 cycles in 25 μl reactions. Aliquots of
8 μl of the amplification products were separated by
electrophoresis on 1 % agarose gels and using β-actin as a
loading control. Each analysis reaction was performed in
duplicates or triplicates.
Western blot
The whole cell lysates were resolved by sodium dodecyl
sulphatepolyacrylamide gel electrophoresis and transferred
onto polyvinylidene difluoride membranes. Blots were
blocked and incubated with the monoclonal antibody
CD133 (1:100), CD44 (1:1000), CD105 (1:500), Oct4
(1:500), Nanog (1:1000), E-cad(1:50; CST), and Vim(1:500;
Santa Cruz) and followed by incubation with a secondary
antibody (1:2000, Santa Cruz, CA, USA). Blots were devel-
oped using an enhanced chemiluminescence detection kit.
For protein loading analyses, a monoclonal β-actin antibody
(1:2000, Santa Cruz) was used as control.
Proliferation assay
In order to compare the proliferation rates between
spheroid cells and adherent cells, 1000 spheroid cells
and adherent cells were exposed to DMEM/F12 medium
containing 10 % FBS, half of the medium was changed
every 3 days and the number of the cells was measured
and the cell growth curve was drawn accordingly. The
proliferation assays were done in triplicate.
Soft agar colony formation assay
Soft agar colony formation assay was performed by
seeding cells in a layer of 0.35 % agar DMEM-F12 over a
layer of 0.5 % agar/DMEM-F12. Cultures were main-
tained in a humidified incubator at 37 °C and 5 % CO2.
Additional complete media was added every 2 days to
continuously supply growth supplements to the cells.
On day 14 or day 21 after seeding, cells were fixed with
pure ethanol containing 0.05 % crystal violet and CFE
quantified by light microscopy [16]. The clone formation
efficiency was the ratio of the number of clones to the
number of seeded cells.
Invasion assays
Transwell chambers (8 μm pore) were first coated with
10 μg/ml fibronectin overnight at 4 °C, washed in PBS and
rehydrated with serum-free media for 30 min at 37 °C.
The media were removed, and then the cells (1 × 105/
chamber) were plated in the upper chambers of the
serum-free media. The lower chambers contained media
with 2.5 % FBS as a chemo attractant. Chambers were
incubated at 37 °C and 5 % CO2. Migrated cells were
stained with crystal violet solution and counted. All tests
were done in duplicate.
Wound healing (Scratch) assay
Parental and spheroid cells were cultured for 24 h. Then
cells were seeded into 6-well plates to 80–90 % conflu-
ence and the cell monolayer was scratched in a straight
line with a 200 μl pipette tip to create a “scratch”. Debris
was removed with PBS and then the culture was re-fed
with fresh medium. Images were taken at 0 and 24 h
after the scratch to calculate the cell migration rate.
Aldefluor assay by FACS
The ALDEFLUOR kit (Stem Cell Technologies, Durham,
NC, USA) was used to analyze the population with a
high ALDH enzymatic activity. Cells obtained from
Table 1 Premier sequences and product sizes
Genes Sense primers Antisense primers Products (bp)
β-Actin 5′- CGGGAAATCGTGCGTGAC -3′ 5′- GAAGGAAGGCTGGAAGAGTG -3′ 183 bp
CD44 5′- AATCCCTGCTACCACTTT -3′ 5′- TTTCTTCATTTGGCTCCC -3′ 191 bp
CD133 5′- TTACGGCACTCTTCACCT -3′ 5′- TATTCCACAAGCAGCAAA -3′ 172 bp
CD105 5′- TTTGGTGCCTTCCTCATCG -3′ 5′- GGTTGGTGCTGCTGCTCT -3′ 136 bp
Nanog 5′- CCTATGCCTGTGATTTGT -3′ 5′- GTTGTTTGCCTTTGGGAC -3′ 160 bp
OCT4 5′- GGTTCTATTTGGGAAGGTGTT -3′ 5′- TGCTGGGCGATGTGGCTGA -3′ 279 bp
CD31 5′- GCCAACTTCACCATCCAG -3′ 5′- CACCCTCAGAACCTCACTTA -3′ 420 bp
CD34 5′- TTGCTGCCTTCTGGGTTC -3′ 5′- CATTTGATTTCTGCCTTGAT -3′ 458 bp
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adherent or spheroid 109 cells were suspended in ALDE-
FLUOR assay buffer containing ALDH substrate and in-
cubated during 40 min at 37 °C. As a negative control,
for each sample of cells an aliquot was treated with
50 mmol/L diethylaminobenzaldehyde (DEAB), a spe-
cific ALDH inhibitor. FACS was performed using a
FACS Aria flow cytometer (BD Biosciences).
Endothelial cell differentiation and characterization
We collected spheroid cells, washed with PBS, then added
the induced medium which contained DMEM, 10 % FBS,
VEGF (10 ng/mL), and bFGF (20 ng/mL). The culture
were maintained for 14–21 days by induced medium and
exchanged every 3 days. To examine the uptake of Dill-
labeled ac-LDL (Bio-medical Technologies, Stoughton,
MA), spheroid cells and differentiated endothelial cells
were incubated with 10 μg/ml Dill-labeled ac-LDL for 4 h
at 37 °C. After incubation, cells were washed three times
with PBS, fixed with 3 % paraformaldehyde for 30 min. To
investigate tube formation Assay, spheroid cells and differ-
entiated endothelial cells (5000 cells) were seeded on the
surface of the matrigel well, and were serum starved in
DMEM medium for 2 h. Thereafter, they were exposed to
DMEM supplemented with 5 % FBS for 24 h. Tube forma-
tion was visualized using a microscope.
Statistical analyses
All experiments were performed at least three times and
representative results were presented (quantitative data
expressed as the mean ± SD). Statistical significance was
set at P < 0.05.
Results
Detection of spheroid cells of SN12C
Previous studies demonstrated that stem cells were able
to form spheres in the serum-free culture. We put the
SN12C (Fig. 1a) into this stem cell selective condition.
The floating cells aggregated into spheroid clusters after
10 days when they were placed in the serum-free
DMEM-F12 supplemented with EGF, bFGF, and B27
every 48 h. Sphere-forming cells were collected 2 weeks
later, each composed of 100–200 cells (Fig. 1b). The self-
renewing capacity of these spheroid body-forming cells
was assessed by dissociating them into single cell and
growing in serum-free medium described in the methods
section. SN12C subsphere can be continuously passage
every 2 weeks about three or four times, without the cell
shape being changed (Fig. 1c).
Spheroid cells exhibit high tumorigenicity
We examined whether smaller numbers spheroid cells
(compared with adherent cells) were capable of tumori-
genesis, as previously shown in other cancer TICs.
Different numbers of parent, spheroid cells were inocu-
lated into BALB/C mice to observe their ability to form
tumors. At 12 weeks after cell inoculation, 104,105 and
106 spheroid cells developed tumors in 2/3, 3/3, 3/3
mice, separately, whereas 1/3 mice injected with 106-
adherent cells and 3/3 mice injected with 107 adherent
cells were tumorigenic (Fig. 2.a1). The growth rates and
the average tumor volumes were significantly different
(Fig. 2.a2, Table 2). We found that only 104 spheroid
cells could form tumor, however, more than 106 adher-
ent cells were required to form tumor in nude mice in a
3-month period. This was 100 times higher than that of
spheroid body-forming cells. The tumor latency was 1–2
months by spheroid cells. As few as 105 spheroid cells
injected subcutaneously initiated 100 % tumor develop-
ment in 4 weeks, but the same number of adherent cells
was unable to form tumor in 3 months (Fig. 2b; Table 3).
Hematoxylin and eosin (H&E) staining of the spheroid
cell xenografts showed well differentiated tumors of typ-
ical “clear cell” morphology (Fig. 2c).
Fig. 1 Micrograph representative of adherent cells and spheroid cells generated from SN12C cells by SFM. a The adherent cells. Bar = 25 μm. b Examples
of spheroid cells isolated from SN12C adherent cells which were placed in the serum-free culture. Bar = 50 μm. c Spheres passaged continuously for three
times. Representative staining of three independent experiments is shown
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Spheroid cells show increased angiogenesis
Our findings suggested that spheroid cells were highly
more tumorigenic than the adherent cells. Microscopic-
ally, most dense tumor cells and abundant vessels were
distributed in xenograft tumors derived from spheroid
cells (Fig. 2c). Sometimes tumor cells seemed in contact
with the lumen directly where did not show endothelium
covering. Furthermore, immunohistochemical staining
revealed that tumor cells which formed blood vessels tube
or dispersed irregularly in the wall of tumor vessels, were
stained positive to anti-human CD34, suggesting tumor
cells with human origin could participate in formation of
functional tumor vessels directly. Thus, increased tumor
angiogenesis is a general property of SN12C-derived
spheroid cells.
Spheroid cells overexpression TIC-related genes and
proteins
To elucidate whether spheroid cells could enrich cells ex-
pressing cell markers associated with renal progenitor cells
or RCC stem cells, spheroid cells and adherent cells were
stained for CD44, CD133,CD105, Oct4 and Nanog by
immunofluorescent (Fig. 3a), flow cytometry (Fig. 3.b1,b2),
Fig. 2 Tumorigenecity of spheroid and adherent cells in vivo. a1 Representative xenograft tumors derived from 106,107 adherent cells and 104,105,106
spheroid cells. a2 BALB/C mice injected with different number of spheroid cells and adherent cells that developed tumors and the tumor volumes
were quantified. b Representative xenograft tumors derived from 105 cells. All mice formed tumors with spheroid cells, but not with adherent cells.
c The H&E staining, immunostained with rat anti-mouse and mouse anti-human CD34 antibody of the tumors formed by spheroid cells and adherent
cells (magnification × 100). Representative the blood microvessel density(MVD) and vasculogenic mimicry (VM) in tumors derived from spheroid cells
and adherent cells was measured. The experiment has been repeated once with a similar outcome. (Magnification × 100). Representative staining of
three independent experiments was shown
Table 2 In vivo tumorigenicity of different cell doses SN12C
spheroid and adherent cells
SN12C Spheroid Adherent
Injected cell number 106 105 104 103 107 106 105 104
Tumor incidence 3/3 3/3 2/3 0/3 3/3 1/3 0/3 0/3
Tumor incidence refers to the numbers of tumor formed/numbers of injection
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reverse transcription PCR (RT-PCR) (Fig. 3.c1,c2) and
Western blot (Fig. 3.d1,d2). All experiments showed that
CD44, CD133, Oct4, Nanog and CD105 were expressed
higher than adherent cells (P < 0.05). These data indicate
that spheroid cells from RCC overexpression stem cell
genes under stem cell-selective conditions and lose or
12decrease these gene expressions under differentiation
conditions.
Spheroid cells have high proliferation and migration
potential
We measured the proliferative and migration potential
of spheroid cells and adherent cells by cell growth curve,
clone formation assay, cell transwell assay and wound
healing assay. The cell growth rate was calculated on the
Table 3 In vivo tumorigenicity of 105 SN12C spheroid and
adherent cells
SN12C Spheroid Adherent
Injected cell number 105 105
Tumor incidence 3/3 0/3
Tumor incidence refers to the numbers of tumor formed/numbers of injection
Fig. 3 TICs-phenotype detection of spheroid and adherent cells. Representative photomicrographs depicting the higher expression of CD44,
CD133, CD105, OCT-4 and Nanog in spheroid cells than adherent cells. a Immunofluorescence staining. Nuclei were labeled with DAPI (blue). Bar
= 25 μm (adherent cells) or 100 μm (spheroid cells). b1, b2 Representative flow cytometric analyses of spheroid cells and adherent cells stained
for stem markers. c1, c2 Semiquantitative RT-PCR was performed for analyzing expression of stem genes in the spheroid cells and adherent cells
and the expression of these TICs-related genes in spheroid body cells were higher than that of adherent cells. d1, d2 Spheroid cells were
enriched for expressing stem proteins by western blot analysis. * Significant differences were detected between stem markers of spheroid cells
and adherent cells. Representative staining of three independent experiments is shown
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2nd day after plating. Figure 4a showed that spheroid
cells had significantly greater proliferated rate than
adherent cells (P < 0.05). We trypsinized spheroid cells
and adherent cells then subjected to soft agar colony
formation assays. Our studies showed that spheroid
cells exhibited higher clone forming ability and formed
more colonies than adherent cells. The SN12C spheroid
cells had a colony forming efficiency (CFE) of 16.4 ±
3.2 % and the adherent cells had a lower CFE of 4.9 ±
1.8 % (P < 0.001; Fig. 4.b1, b2). The invasion assay
mimics the in vivo situation more closely. As shown in
Fig. 4c, very few adherent cells invaded into matrigel
while significantly more spheroid cells invaded into
matrigel after 3 days of culture. Spheroid cells had
higher invasion ability than their adherent cells
detected on day1, 2, and 3 (Fig. 4.c1, c2). The
observation that spheroid cells migrated quicker than
their adherent cells was further confirmed by a wound
healing assay. As shown in Fig. 4d1 and d2, more
spheroid cells migrated into the scratch than adherent
cells.
Spheroid cells have high ALDH1 activity
ALDH expression has been suggested as a potential
functional marker for TICs. To confirm this finding, we
utilized the ALDEFLUOR assay to assess the size of the
population with ALDH enzymatic activity in the
SN12C cell line. ALDEFLUOR-positive cells were
enriched by 6 fold in spheroids, compared to the
adherent cells. These results suggest that ALDH1-
positive cells represent the stem/progenitor population
of RCC (Fig. 5).
Fig. 4 Characterization of SN12C spheroid cells and adherent cells by cell growth curve, clone formation assay, transwell assay and wound
healing assay. a The growth curves of spheroid cells and adherent cells for 7 days. Spheroid cells proliferate at a significantly (P < 0.05) greater
rate than adherent cells. The experiment has been repeated twice. b1, b2 An increase clone formation in cell was observed and measured in
spheroid cells when compared with the adherent cells. Bar = 25 μm. c1, c2 The transwell invasion tests showed that spheroid cells resulted in an
increased migration rate when compared with the adherent cells. Bar = 25 μm. d1, d2 Spheroid cells recovered ‘scratch’ made by 200 μL pipette
tip after 24 h more efficient than their adherent cells. * Significant differences were detected between aggressive growth patterns of spheroid
cells and adherent cells. Experiments were repeated three times with similar results
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Spheroid cells have upregulation EMT-associated proteins
To demonstrate whether there were connections between
the malignant profiles of spheroid cells and epithelial–mes-
enchymal transition (EMT), we detected their EMT-
phenotype. The results of Western Blotting showed that
Vim was higher in spheroid cells compared to adherent
cells, whereas E-cadherin was lower in spheroid cells com-
pared to adherent cells (Fig. 6). Together, these features of
EMT strongly suggested a possible relationship with the TIC
phenotype.
Differentiation of spheroid cells into endothelial-like cells
in vitro
In order to investigate whether spheroid cells from RCC
cell lines have ability to differentiate endothelial in vitro,
we cultured spheroid cells in a medium containing 10 ng/
ml VEGF. We observed isolated starting clones after 7 to
15 days of culture. Surprisingly, these clones, which appar-
ently grew randomly, were easily differentiated according
to their morphology, one type being cobble stone (Fig. 7a).
In order to determine the phenotype of cell populations,
we performed RT-PCR and flow cytometry analysis. The
cobble stone population was uniformly positive for endo-
thelial markers such as CD31 and CD34 (Fig. 7b). These
results were confirmed by Western blotting analysis
(Fig. 7c). In addition, these cells incorporated acetylated
LDL (Fig. 7d). Taking into account their morphology,
biochemical markers and functional capacity, we demon-
strated that cobblestone cells were ECs.
Discussion
Currently, there is data to demonstrate that spheroid
body culture has been increasingly used as a method for
enriching stem cells which relies on their property of
anchorage-independent growth. Various types of poten-
tial TIC subpopulations from primary tumors have been
reported to be isolated and enriched by the application
of spheroid body culture [17, 18]. The spheroid body-
forming cells from primary tumors, such as ovarian
cancer and breast cancer, showed stem-like properties
and expressed their TIC markers [14]. Since the markers
of renal TICs were uncertain, it is unimaginable to
isolate cells using all the markers. Also, to our know-
ledge, there have been few reports on the isolation and
characterization of renal TICs by the method of spher-
oid culture, therefore, we isolated spheroid body cells by
Fig. 5 Comparative FACS analysis of ALDH-positive cells of adherent (upper, 2.5 %) and spheroid (bottom, 12.6 %) cells from SN12C
Fig. 6 The comparative expression EMT markers in adherent cells and
spheroid cells. Spheroid cells were higher expression of Vimentin, but
lower expression of E-cadherin, comparing with the adherent cells
Zhang et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:163 Page 8 of 11
cultivating human RCC cell line SN12C in defined
serum-free medium. In this report, we demonstrated
that spheroid cells could generate greater numbers of
new spheroid cells than the parental cells. These
observations indicated that spheroid body-forming cells
were capable of self-renewal and proliferation, which
were important characteristics of TICs.
The gold standard assay of TICs is that the candidate
population of cells can preferentially initiate tumor de-
velopment in animals [19]. The least stringent definition
is that the prospectively purified TICs population is
much more tumorigenic than the bulk or the tumor cell
population in a suitable tumor development assay. Our
findings suggested that 104 spheroid cells from primary
tumor cells engrafted into mice and allowed full recap-
itulation of the original tumor, whereas 106 adherent
cells remained non-tumorigenic, which indicated spher-
oid cells were more tumorigenic than the corresponding,
and the tumor formation ability of the spheroid cells
overall was at least 100-fold higher than that of adherent
cells. Although the adherent cells could produce tumors
when large numbers of cells were implanted, the tumors
that formed regressed spontaneously, whereas the
spheroid-derived tumors continued to grow, indicating
that the adherent cells-derived tumors may lack the TICs
required sustaining tumor growth. The initial formation
of tumors from high numbers of adherent cells may be
explained by the high intrinsic tumorigenicity of SN12C
cells, a high fraction of which express TICs markers.
To further explore the TIC properties of spheroid
body-forming cells, we evaluated the spheroid cells for
their stemness characteristics. Our recent work has
Fig. 7 Functional analysis of spheroid-derived endothelial cells (spheroid-EC). a Morphological analysis of spheroid cells, spheroid-EC differentiated
at 10 ng/ml VEGF, and HUVEC. b Flow cytometry analysis of CD31 and CD34 expression in spheroid cells, spheroid-EC, and HUVEC. c1,c2 The
comparative expression of CD31 and CD34 in spheroid cells, spheroid-EC, and HUVEC. d Assessment of network formation by spheroid cells,
spheroid-EC, and HUVEC on Matrigel. e Fluorescence imaging of acetylated low-density lipoprotein (red) and spheroid cells, spheroid-EC, and
HUVEC metabolizing ac-LDL
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shown overexpression of stem cell-specific transcription
factor such as CD44, CD133, Oct4, CD105 and Nanog is
vital characteristic of TICs [20–22]. Bussolati et al. re-
ported the isolation of CD105+ cancer stem cells from
renal carcinoma [23]. In this study, we demonstrated
that CD44, CD133, Oct4, CD105 and Nanog were over-
expressed in spheroid cells compared with parental cells
by immunofluorescent, FCM, RT-PCR and Western blot
analysis with statistical significance. So it is conceivable
that the expression of CD44, CD133, Oct4, CD105 and
Nanog in spheroid cells will endow some cells with cer-
tain stem/progenitor cell properties. Strikingly, spheroid
cells showed approximately threefold increase in CFE
when compared with that of adherent cells on soft agar,
suggesting that spheroid cells have a higher self-renew
potential than adherent cells. Spheroid cells showed
higher migration ability than their adherent cells both in
migration and wound healing assays, which were in line
with Yu et al.[24], indicated that spheroid cells might
promote more aggressive biological behavior. ALDHs
are a superfamily of 17 intracellular enzymes that pro-
tect cells from the cytotoxic effects of peroxic aldehydes.
Increased ALDH activity has also been found in stem
cell populations in various types of cancer. ALDH activ-
ity may therefore provide a marker for normal and ma-
lignant stem as well as progenitor cells. Our study
indicated that a high ALDH enzymatic activity is a func-
tion of RCC tumor-sphere.
Several intriguing studies have described that RCC
cells developmental epithelial-to-mesenchymal transition
(EMT) program to enrich their stemness features,
thereby facilitating metastasis and drug resistance [25].
This is an important function, because a loss of E-cad-
herin on the cell surface has been shown to play a role
in tumor progression and metastasis. In our study,
spheroid cells demonstrated down-regulation of E-
cadherin, and up-regulation of Vimentin. So, the spher-
oid cells display the phenotype of EMT according to our
results. And the biological behaviors of spheroid cells
consistent with the mesenchymal cells, such as morpho-
logical character, lower adhesion but higher in vitro
migratory/invasive capacity.
Recently many accumulative evidences have showed
that TICs may participate in the angiogenesis process to
form endothelial cells directly [26]. It has been reported
that two kinds of distinct tumor vessels play function in
tumor blood-supply in malignant tumor tissues, one of
which is VM, where vessels are exclusively composed of
tumor cells; and the other is the endothelium vessel
(EDV), where vessels are covered by the endothelium
[27]. We previously also showed definite relationship
between TICs, microvessel density (MVD), and VM
[20]. In this study, we found spheroid cells not only
formed xenograft tumors in vivo, histopathological
studies have also found that some cells composing of
tumor vessel lumen showed anti human CD34 positive,
indicating these cells in the vessel wall of xenograft
tumors were originated from the cells of human origin,
not derived from host (murine) cells, which suggested
that TICs might be the progenitor for tumor vascula-
ture. This finding is consistent with recent reports that
tumors grown from brain TICs, isolated based on the
marker CD133, are more angiogenic than non-TIC-
derived tumors [28], and that C6 glioma-derived TICs,
isolated by a sphere-forming assay, exhibit increased
microvessel density and blood perfusion compared with
non-TIC-derived tumors [29]. Endothelial differentiation
of spheroid cells were morphologically similar to
HUEVC and, and displayed functional characteristics of
fully mature endothelial cells. Vasculogenic potential of
these cells was shown by assessing formation of net-
works when plated on a semi-solid substrate, and intern-
alization of ac-LDL distinctly identified endothelial cells
based on metabolic activity. These results suggest that
spheroid cells are able to differentiate into functional
endothelial cells in vitro and are suited for evaluation for
vasculogenic potential within a tissue-engineered con-
struct in vivo.
Together, these findings support the hypothesis that
TICs promote tumor angiogenesis by secreting elevated
levels of pro-angiogenic factors compared to non-TIC
populations [30]. Work is in progress in our laboratory to
target the specific mechanisms by which spheroid cells in-
creased angiogenesis. Further investigation of the molecu-
lar mechanisms responsible for the increased angiogenesis
seen in TIC-derived kidney tumors may improve the effi-
cacy of cancer therapies that target angiogenesis, either
alone or in combination with chemotherapy [31].
Conclusions
In summary, we isolated RCC spheres from SN12C kidney
cancer cell line and showed that they exhibit tumor initiat-
ing cells properties including high tumorigenic capacity in
xenograft model, higher self-renew potential, overexpres-
sion of TICs markers, high clonogenicity and increased an-
giogenic potential. Further experiments using more refined
selection criteria such as a combination of two or multiple-
markers would be useful to specifically identify and purify
TICs.
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